In summary, our research findings suggest that NEAT1 exhibit elevated expression levels in gliomas, especially in cases that recurred, and TMZ effectively enhances the response of GBM cells to NEAT1 inhibition. The gene discussed is NEAT1; the disease is central nervous system cancer.